Search

Three-dimensional multiple-input multiple-output (3D MIMO) and large-scale MIMO are two promising technologies for upcoming high data rate wireless communications, since the inter-user interference can be reduced by exploiting antenna vertical gain and degree of freedom, respectively. In this paper, we derive the achievable sum rate of 3D MIMO systems employing zero-forcing (ZF) receivers, accounting for log-normal shadowing fading, path-loss and antenna gain. In particular, we consider the prevalent log-normal model and propose a novel closed-form lower bound on the achievable sum rate exploiting elevation features. Using the lower bound as a starting point, we pursue the "large-system" analysis and derive a closed-form expression when the number of antennas grows large for fixed average transmit power and fixed total transmit power schemes. We further model a high-building with several floors. Due to the floor height, different floors correspond to different elevation angles. Therefore, the asymptotic achievable sum rate performances for each floor and the whole building considering the elevation features are analyzed and the effects of tilt angle and user distribution for both horizontal and vertical dimensions are discussed. Finally, the relationship between the achievable sum rate and the number of users is investigated and the optimal number of users to maximize the sum rate performance is determined. [ABSTRACT FROM AUTHOR]

Background and objective: The absence of α-gal in humans is caused by the inactivity of α-1,3GT gene. However, humans have pre-existing and abundant anti-gal antibodies. Xenotransplantation procedures have indicated the high potential of introducing α-1,3GT gene to synthesize α-gal for cancer gene therapy by mimicking hyper-acute rejection. The aim of this study is to construct a lung cancer A549 cell line that expressed α-gal, and to observe the antitumor mechanisms mediated by human serum. Methods: A549 cells were transfected with pEGFP-N1-GT plasmids constructed in a previous study. A stable transgenic cell line, A549-GT, was then selected and cultivated. The biological characteristics of A549-GT cells, including morphology and proliferation, were examined. α-1,3GT mRNA expression was detected by RTPCR. Direct immunofluorescence staining and flow cytometry (FCM) were used to analyze the synthesis of α-gal in A549- GT. The binding of human serum IgM and C3 with A549-GT were also detected. Results: α-1,3GT mRNA was expressed in A549-GT. Direct immunofluorescence staining and FCM indicated a high and stable α-gal expression rate in A549-GT. Compared with parental A549 cells, the biological characteristics of A549-GT were unaltered. α-Gal expression was not detected in the human fetal lung fibroblast cell line MRC-5 even though A549-GT and its culture medium were cultivated with the enzyme. Immunofluorescence staining and FCM also indicated abundant binding between A549-GT treated with human serum and IgM/C3. Conclusion: α-Gal expression in tumor cells by gene transduction can induce complement-dependent cytototic antitumor effects. [ABSTRACT FROM AUTHOR]

In this paper, the adsorption equilibrium and kinetic behaviors of pentachiorophenol (PCP) on suspended particulate matter (SPM) in Donghu Lake water were investigated. The Langmuir and Freundlich adsorption models were applied to describe the equilibrium isotherms and their constants were evaluated. The results indicated that the adsorption of PCP on Donghu Lake SPM followed the Freundlich isotherm. Furthermore, the first order Lagergren rate equation and the pseudo-second order rate equation were used to describe the kinetic behaviors of PCP adsorption on Donghu Lake SPM, the rate constants were determined, and the kinetic process of the adsorption of PCP on Donghu Lake SPM followed the second order kinetic model. [ABSTRACT FROM AUTHOR]

The pharmacokinetic parameters of two oral formulations of rizatriptan (CAS 144034-80-0, a capsule preparation as test and rizatriptan tablet as reference), given at a single dose of 10 mg each, were compared in an open-label, randomized, single oral dose, two-period cross-over design in 20 healthy volunteers under fasting conditions. Plasma concentrations of rizatriptan were measured by a validated HPLC assay. The parametric 90 % confidence intervals of the geometric mean values of the test/reference ratios were 91.9 % to 101.9 % (point estimate: 97.3 %) for AUC0-∞, 93.0 % to 102.2 % (point estimate: 96.5 %) for AUC0-t, 90.1 % to 100.0 % (point estimate: 95.4 %) for Cmax, being within the acceptance criteria for bioequivalence (80 %–125 %). Tmax values were analyzed by the nonparametric Wilcoxon test and the difference was not statistically significant. Therefore, it is concluded that the test and reference rizatriptan formulations are bioequivalent with regard to both the extent and the rate of absorption. [ABSTRACT FROM AUTHOR]